KORU Medical Systems, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRMD research report →
Range $6 – $6
Price Chart
About the company
KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably their FREEDOM infusion systems.
- CEO
- Adam Kalbermatten
- IPO
- 1994
- Employees
- 73
- HQ
- Mahwah, NY, US
Get TickerSpark's AI analysis on KRMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $138.37M
- P/E
- -180.23
- Fwd P/E
- 106.33
- PEG
- -0.97
- P/S
- 2.99
- P/B
- 0.00
- EV/EBITDA
- -2256629372.64
- Div Yield
- 0.00%
- Gross Margin
- 63.20%
- Op Margin
- -1.29%
- Net Margin
- -1.78%
- ROE
- -0.00%
- ROIC
- -0.00%
Latest fiscal year · YoY change
- Revenue
- $41.13M+22.2%
- Gross Profit
- $25.60M+20.0%
- Op Income
- $-2,972,442
- Net Income
- $-2,637,926+56.5%
- EPS
- $-0.06+56.1%
- OCF Growth
- +244.6%
- FCF Growth
- +70.9%
- 52W High
- $6.61
- 52W Low
- $2.86
- 50D MA
- $3.18
- 200D MA
- $3.86
- Beta
- 0.39
- RSI (14)
- 46
- Avg Volume
- 223.45K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
KORU delivered 11% revenue growth, expanded margins, and returned to positive profitability while raising full-year guidance and pointing to a stronger Q4.· November 10, 2026
- Q3 revenue was $11.6 million, up 11% year over year, with gross margin expanding to 65.2% from 60.2%.
- The company posted its second straight quarter of positive net income and adjusted EBITDA, and management said Q4 is expected to reaccelerate.
- Domestic core remained strong; reported revenue grew 32% year over year, while normalized domestic core growth was 10% and normalized international core growth was 23%.
- Management raised full-year 2026 guidance: revenue to $48.0 million-$48.5 million, gross margin to 63%-64%, and year-end cash to above $8 million.
- Strategic progress included new distribution partnerships in Europe and Africa, 3 U.S. specialty pharmacies dispensing RYSTIGGO, and continued advancement in the pipeline and Freedom360 development.
KORU reported third-quarter revenue of $11.6 million, up 11% year over year. Gross margin was 65.2%, compared with 60.2% a year ago, a 500 basis point improvement. Domestic core revenue grew 32% year over year on a reported basis and 10% on a normalized basis; normalized international core revenue increased 23%, while pharma services and clinical trials declined 27%. Net income was positive by $200,000 and adjusted EBITDA was also positive for the second consecutive quarter. For full-year 2026, management raised revenue guidance to $48.0 million-$48.5 million (17%-18% growth), raised gross margin guidance to 63%-64%, expects positive adjusted EBITDA for the year, and increased the year-end cash target to above $8 million.
Adam Kalbermatten’s message was that the quarter was about underlying quality and strategic momentum more than just the headline growth rate. He said the business is executing across domestic and international markets, adding new distribution partnerships, and advancing multiple pipeline and product-development initiatives that could drive the next phase of growth. His tone was upbeat and confident, but he repeatedly cautioned that some new initiatives will take time and that guidance should be viewed within the context of a recurring, profitable core business.
Tom Adams emphasized operating leverage and margin expansion. He cited 65.2% gross margin versus 60.2% last year, noting lower manufacturing costs, favorable geographic mix, and the extended CMO supply agreement as the main drivers. He said cash ended the quarter at $7.4 million after $900,000 of usage, with the usage driven by working capital for inventory and accounts receivable; he also said the company has access to an unused $10 million debt facility and expects positive cash flow in Q4. Year to date, revenue was $35.4 million versus $30.2 million last year, gross margin was 64% versus 62.1%, and adjusted EBITDA improved to $2.2 million from $100,000.
Analysts focused on the cadence of international revenue into 2027, the health of the SCIg market, the company’s most confident 2027 growth drivers, and the ramp of new European markets and Freedom360. Management said the new Europe and Africa agreements have initial orders in place, benefits should begin in Q4, and 2027 should see continued new patient starts, but they would not quantify specific 2027 revenue yet. On the SCIg market, Adam Kalbermatten said growth appears to be running around 8% to 10% year over year, and when pressed on growth assumptions, he said U.S. growth around 10% to 15% is a fair working assumption while international should remain above market. He also estimated current European market share at roughly 20% and said Freedom360 should begin adding value in the back half of next year after 510(k) approval.
The call showed a business with recurring revenue, expanding margins, and improving profitability, and management raised guidance rather than cutting it. New European and African distribution deals, live specialty pharmacy activity for RYSTIGGO, and a pipeline spanning SCIg, deferoxamine, enzyme replacement, nephrology, and connected health all give the company multiple potential growth drivers.
Q3 revenue growth slowed versus what management wanted, and they explicitly said international growth moderated because of timing and market-entry issues. Several of the more meaningful pipeline opportunities are still dependent on pharma partners, regulatory timing, or future trials, and management would not provide near-term detail on oncology or 2027 specifics. There is also continued mix sensitivity in international markets and reliance on inventory timing and partner execution to deliver the expected Q4 reacceleration.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.2%
- Shares Outstanding
- 43.38M
- Float Shares
- 40.44M
of shares held by institutions
88 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| First Light Asset Management, LLC | 3.39M | ▼ 380.48K |
| Topline Capital Management, LLC | 3.37M | ▼ 141.07K |
| Blackrock, Inc. | 2.78M | ▲ 153.37K |
| Vanguard Group Inc | 2.21M | ▲ 61.93K |
| Vanguard Capital Management LLC | 1.69M | ▼ 127.39K |
| Geode Capital Management, LLC | 1.04M | ▼ 87.39K |
| Meros Investment Management, LP | 759.66K | ▼ 787 |
| Simcoe Capital LLC | 713.39K | ▼ 114.00K |
| Archon Capital Management LLC | 642.92K | 0 |
| State Street Corp | 634.33K | ▼ 12.24K |
| Hrt Financial LP | 375.70K | ▲ 22.53K |
| Northern Trust Corp | 347.17K | ▲ 24.92K |
Held by 95 ETFs
Biggest fund positions in KRMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 20, 26 | Manko Joseph M. Jr. | other | 43,208 |
| Nov 13, 26 | Schiller Eric | buy | 8,546.09 |
| Sep 30, 26 | Manko Joseph M. Jr. | other | 5,119 |
| Oct 1, 26 | CASCELLA ROBERT | other | 5,119 |
| Oct 1, 26 | Matin Shahriar | other | 5,119 |
| Oct 1, 26 | FLETCHER R JOHN | other | 7,679 |
| Oct 1, 26 | French Donna | other | 5,119 |
| Oct 1, 26 | WHOLIHAN EDWARD | other | 5,119 |
| Sep 8, 26 | KALBERMATTEN ADAM R | buy | 32,000 |
| Jul 28, 26 | KALBERMATTEN ADAM R | other | 75,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KRMD coverage
Recent articles, reports, and earnings notes.
No research on KRMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KRMD report →KORU Is On The Mend
seekingalpha.com · Nov 13
KORU Medical Systems, Inc. (KRMD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
What KORU Medical Systems (KRMD) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA
businesswire.com · Nov 10
KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026
businesswire.com · Oct 20
Reviewing Organigram Global (NASDAQ:OGI) & KORU Medical Systems (NASDAQ:KRMD)
defenseworld.net · Sep 21
KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 6
KORU Medical Systems Q2 Earnings Call Highlights
marketbeat.com · Aug 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.